<!DOCTYPE html>
<html lang="en">
    <head>
        <title>displaCy</title>
    </head>

    <body style="font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr">
<figure style="margin-bottom: 6rem">
<div class="entities" style="line-height: 2.5; direction: ltr">%%%%%%%%%%NEW-RECORD%%%%%%%%%% &quot;Discharge summary&quot; &quot;Report&quot;</br>13599,2398,138345,2189-04-03,,,&quot;Discharge summary&quot;,&quot;Report&quot;,,,&quot;Admission Date:  [**2189-4-1**]       Discharge Date:  [**2189-4-3**]</br></br>Date of Birth:   [**2131-8-12**]       Sex:  M</br></br>Service:</br></br>HISTORY OF PRESENT ILLNESS:   Mr. [**Known lastname 10840**] is a 57 year old</br>gentleman with a past medical history of Parkinson's Disease,</br>depression, anxiety, seizure disorder, coronary artery</br>disease status post inferior myocardial infarction, who was</br>found to be confused and walking in the streets disoriented</br>on the evening of the 14th.  EMS was called and he was</br>brought to [**Hospital1 69**] where he had</br>an altered mental status.  In the Emergency Department, he</br>was found to have an [**Hospital1 **] CK to 5,000, negative MB</br>fraction of less than 1% with a positive [**Hospital1 **] up to 20.</br>He had no EKG changes, however, he did have evidence of an</br>inferior myocardial infarction with Qs in the inferior leads</br>with a tall R wave in V2 consistent with a posterior</br>involvement.</br></br>The patient also had a bedside echocardiogram in the</br>Emergency Department which showed an ejection fraction of</br>approximately 30% with left ventricular dilation and global</br>left ventricular dysfunction, one plus aortic regurgitation,</br>three plus mitral regurgitation.  The patient was found to</br>have a white count [**Hospital1 **] to 17.4, being afebrile and an</br>anion gap was 17 with ketones in his urine.  He had a</br>negative head CT scan.  He had an lumbar puncture with 560</br>red blood cells in tube four, 470 in tube one, one white</br>blood cell, protein 49, glucose 70, no PMNs, no organisms on</br>Gram stain.</br></br>The patient initially received a dose of 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ceftriaxone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
,</br>
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Acyclovir
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Vancomycin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.  The patient had a follow-up MRI /</br>MRA with no abnormalities.</br></br>The Cardiology Team was consulted and did not feel that the</br>patient was having an acute event that required cardiac</br>catheterization at the time of admission, and that the</br>patient's neurological mental status was more important as an</br>acute issue.  They recommended medical management.</br></br>The patient was started on 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aspirin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    beta blocker
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ACE
inhibitor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and a 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    statin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.  Neurosurgery was consulted regarding</br>the red blood cells in the lumbar puncture tube.  They</br>recommended an MRI which showed no acute bleed or acute</br>parenchymal process.</br></br>Over the patient's Emergency Department course, the patient's</br>mental status improved.  He was alert and oriented times</br>three.  He did not recall the events of the day of admission.</br>He said he has been under a lot of stress with his car being</br>stolen last week.  He also reported running out of his</br>medicines and not taking them.</br></br>He reports having dreams that are like seizure-like events in</br>the evening.  He does not recall when his last seizure was</br>except for this &quot;&quot;seizure events&quot;&quot;.</br></br>PAST MEDICAL HISTORY:</br>1.  History of seizure disorder.</br>2.  Parkinson's Disease.</br>3.  Coronary artery disease.</br>4.  Depression.</br>5.  Anxiety / post-traumatic stress disorder.</br></br>ALLERGIES:   No known drug allergies.</br></br>MEDICATIONS AS AN OUTPATIENT:</br>1.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lamictal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 150 twice a day.</br>2.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Venlafaxine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br>3.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Klonopin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1 twice a day.</br>4.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lorazepam
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1 q. h.s.</br>5.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sinemet
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 25/100 three times a day.</br>6.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sinemet CR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 50/200, one tablet four times a day.</br>7.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mirapex
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 one three times a day.</br>8.  He had a history of taking 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Metoprolol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 25 twice a day,</br>although according to his primary care physician who was</br>consulted, she said that he was noncompliant.</br></br>SOCIAL HISTORY:   The patient lives alone.  He had been a</br>mail carrier until a car accident.  He was in a motorcycle</br>accident in [**2187-6-20**].  Since then, he has been on</br>disability.  Parkinson's for six years.  Care in the VA</br>system with Dr. [**Last Name (STitle) 41058**] at the [**Hospital1 1559**] VA as the patient's</br>primary care physician.</br></br>PHYSICAL EXAMINATION:   On presentation, temperature 98.0 F.;</br>pulse 96; blood pressure 133/60; respiratory rate 20;</br>saturation of 100% on room air.  He was alert and oriented</br>times three, disheveled.  Pupils are equal, round, and</br>reactive to light and accommodation.  Extraocular muscles are</br>intact.   Anicteric sclerae.  No lymphadenopathy, no jugular</br>venous distention.  No bruit.  Clear to auscultation</br>bilaterally.  He has no wheezes, rales or rhonchi.  Heart is</br>S1, S2, regular rate and rhythm, no murmurs, rubs or gallops.</br>Abdomen was nontender, nondistended, soft, with active bowel</br>sounds.  He had no cyanosis, clubbing or edema.  Cranial</br>nerves II through XII were intact.  He had a pill rolling</br>tremor at baseline with increased cogwheel rigidity.</br></br>LABORATORY DATA:  On admission, white blood cell count was</br>17.4, and this was decreased to 12 on the day of discharge.</br>Hematocrit was 39 at admission; 31.7 on the day of discharge.</br>Platelets were 259 at date of admission and 208 on the date</br>of discharge</br></br>Sodium 137, potassium 4.6, chloride 101, bicarbonate 19 with</br>a gap of 17.  BUN 36, creatinine 1.0.  These were all</br>admission labs on the day of discharge.</br></br>The patient's creatinine was down to 0.8, BUN down to 18,</br>anion gap was down to 7.  When the patient presented, he had</br>ketones in his urine.  His toxicology screen was negative for</br>alcohol and all other substances.</br></br>His glucose was within normal limits.  His calcium was 8.8,</br>magnesium 2.0, phosphorus 3.1, lactate was 1.0.</br></br>When he presented, CK 5,712; on the day of discharge, this</br>was down to 1900.  On admission his MB index was less than</br>1.0, his [**Hospital1 **] was 20 at admission.  His MB index is 0.5</br>on the date of discharge, and his [**Hospital1 **] was 6 on the date</br>of discharge.</br></br>Albumin 3.7, total cholesterol 201, triglycerides 48, HDL 45,</br>LDL 146, B12 331, folate 5.5, TSH 1.8.  The patient's</br>
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lamictal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 level is pending.</br></br>The patient's EKG shows sinus tachycardia on admission, left</br>axis deviation, left ventricular hypertrophy as per AVL</br>greater than 11 millimeters.  He has Q waves in the inferior</br>leads and a tall R in V2 consistent with an old inferior</br>posterior myocardial infarction.</br></br>HOSPITAL COURSE BY PROBLEM:</br>1.  This is a 57 year old male who presents with delta MS</br>[**First Name (Titles) **] [**Last Name (Titles) **], [**Last Name (Titles) **] CKs with flat MB index.  For</br>delta MS [**First Name (Titles) **] [**Last Name (Titles) 41059**] includes post-ictal state status</br>post seizure.  The patient mentions having events at night</br>that were consistent with seizures but he was not sure if</br>they were dreams or he was dreaming about having seizures, or</br>actually having seizures.  Delirium secondary to alcohol</br>withdrawal, but his tox screen was negative, although the</br>ketones in his urine and the anion gap were within normal</br>limits, glucose is suggestive of alcoholic ketosis; possible</br>encephalitis but the patient's lumbar puncture and MRI/MRA</br>were not consistent with this; secondary to psychiatric</br>manifestations of his neurological disorder.  The patient</br>carries a diagnosis of Parkinson's and possibly could have</br>[**Last Name (un) 309**] body involvement.  Neurology was consulted and was</br>following the patient.</br></br>An EEG was ordered but the patient refused to participate in</br>the EEG as it would involve the removal of his hairpiece.</br></br>The patient was continued on his 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lamictal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 150 twice a day on</br>his 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sinemet
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 25/100 three times a day, 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Sinemet CR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 50/200 four
times a day, 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mirapex
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 one three times a day.  He was also</br>continued on his 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    venlafaxine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and received 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ativan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 as well</br>p.r.n. for agitation.</br></br>Psychiatric saw the patient and generally thought his picture</br>was one of resolving delirium.  His mental status has</br>gradually improved during his course, although he does have</br>episodes of confabulation, flat affect and poor insight into</br>his overall medical condition.  The patient has threatened to</br>leave against medical advice multiple times during the</br>hospitalization.</br></br>Psychiatric has seen him and felt that he is unable at</br>different times to have insight and weigh the pros and</br>consequences of his leaving the hospital against medical</br>advice at the current time.</br></br>2.  [**Last Name (un) **] [**Last Name (un) **]:  Due to the high [**Last Name (un) **] at 20, the</br>patient denies any chest pain and no EKG changes.  The</br>patient either had a silent non-ST elevation myocardial</br>infarction or demand ischemia possibly secondary to</br>arrhythmia that may have lead to the patient being down.  The</br>[**Last Name (un) **] CKs are consistent with rhabdomyolysis not secondary</br>to a large ST elevation myocardial infarction as the MB index</br>was negative.  The patient was placed on 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    beta blocker
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 37.5</br>three times a day, 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aspirin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 81 q. day; 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ACE inhibitor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 12.5</br>three times a day of 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Captopril
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 10 q. day of 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lipitor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br></br>The patient had an echocardiogram repeated at the bedside.</br>Ejection fraction was less or equal to 25%.  Right atrium</br>mildly dilated and left atrium mildly dilated.  Left</br>ventricular cavity mildly dilated.  Severe global left</br>ventricular hypertrophy, overall systolic left function</br>severely depressed.  Right ventricular chamber size is</br>normal.  Right ventricular systolic function appears</br>depressed.  The aortic root is normal in diameter.  Four plus</br>mitral regurgitation, trivial tricuspid regurgitation, and</br>trace aortic regurgitation.</br></br>3.  ANION GAP ACIDOSIS:  Secondary to ketones, alcohol,</br>starvation.  The patient's anion gap resolved after</br>hydration.</br></br>4.  LEUKOCYTOSIS:  The patient was afebrile with no evidence</br>of fever.  On his hospital stay, blood cultures, urine</br>cultures, sputum cultures were negative.  Chest x-ray showed</br>no evidence of congestive heart failure or pneumonia.  White</br>count decreased to 12 and no evidence of infection.</br></br>5.  NUTRITION:  The patient received intravenous 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fluids
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
</br>secondary to rhabdomyolysis and his anion gap.  As both of</br>these resolved, the 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fluids
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 were discontinued.  The patient</br>was taking p.o. with a cardiac heart healthy diet and low</br>sodium.</br></br>6.  PROPHYLAXIS:  The patient was initially on Pneumoboots</br>and subcutaneous 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heparin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and then was ambulating and</br>requiring these discontinued.  Taking p.o. and not requiring</br>any gastrointestinal prophylaxis.</br></br>He is full code.</br></br>DISCHARGE DIAGNOSES:</br>1.  Change in mental status, delirium.</br>2.  Myocardial infarction.</br>3.  Coronary artery disease.</br>4.  Hyperlipidemia.</br>5.  Hypertension.</br>6.  Parkinson's.</br>7.  Seizure disorder.</br>8.  Post-traumatic stress disorder.</br>9.  Anxiety.</br></br>DISCHARGE MEDICATIONS:</br>1.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cardiolevodopa CR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 50/200, one tablet p.o. four times a
day.</br>2.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lipitor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 10 mg p.o. q. day.</br>3.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Captopril
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 12.5 mg p.o. three times a day.</br>4.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lorazepam
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1 mg p.o. three times a day.</br>5.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Metoprolol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 37.5 mg p.o. three times a day.</br>6.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Aspirin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 81 mg p.o. q. day.</br>7.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lamotrigine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 150 mg p.o. twice a day.</br>8.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mirapex
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1 mg p.o. three times a day.</br>9.  
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Venlafaxine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 450 mg p.o. three times a day.</br>10. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cardiolevodopa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 25/100, one tablet p.o. three times a day.</br>11. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Folic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1 mg intravenously q. day.</br>12. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Thiamine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 100 mg intravenously q. day.</br>13. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Acetaminophen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 325 to 650 mg p.o. q. four to six hours
p.r.n.</br></br></br></br>                     DR.[**Last Name (STitle) **],[**First Name3 (LF) 7853**] C. 12-869</br></br>Dictated By:[**Dictator Info **]</br>MEDQUIST36</br></br>D:  [**2189-4-3**]  14:33</br>T:  [**2189-4-3**]  18:38</br>JOB#:  [**Job Number 41060**]</br>&quot;</br></br>%%%%%%%%%%NEW-RECORD%%%%%%%%%% &quot;Discharge summary&quot; &quot;Report&quot;</br>13600,2398,138345,2189-04-15,,,&quot;Discharge summary&quot;,&quot;Report&quot;,,,&quot;Admission Date:  [**2189-4-1**]       Discharge Date:  [**2189-4-15**]</br></br>Date of Birth:   [**2131-8-12**]       Sex:  M</br></br>Service:  Cardiothoracic Surgery</br></br>HISTORY OF PRESENT ILLNESS:  This is a 57-year-old male with</br>a history of seizure disorder and coronary artery disease,</br>who was brought into the [**Hospital1 69**]</br>Emergency Room on [**2189-4-1**] secondary to confusion.</br>Patient was reportedly found on the street in a confused and</br>disoriented state by emergency medical technicians and</br>subsequently brought to [**Hospital1 69**]</br>for further evaluation and management.  In the Emergency</br>Department, the patient was noted to be disoriented and</br>confused with a CPK of 5712 and a [**Hospital1 **] of 20.</br></br>Patient's electrocardiogram demonstrated sinus tachycardia at</br>112, inferior lead Q waves, and mild ST depression in lead</br>V5.  In addition, the patient was noted to have an [**Hospital1 **]</br>white blood cell count of 17.4, but was noted to be afebrile</br>and hemodynamically stable.  The patient continued to have</br>waxing and [**Doctor Last Name 688**] mental status in the Emergency Department,</br>after which point he received head CT scan which was negative</br>and a lumbar puncture which demonstrated 560 red blood cells</br>and 1 white blood cell.  Due to the patient's [**Doctor Last Name **] CK and</br>[**Doctor Last Name **], Cardiology consult was obtained in the Emergency</br>Department.</br></br>A bedside echocardiogram was performed, which demonstrated</br>hypokinesis with an ejection fraction of approximately 30%</br>and 2+ mitral regurgitation.  Initial Cardiology</br>recommendations advised conservative management with a 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    beta
blocker
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, but no Heparinization given the patient's lumbar</br>puncture results.</br></br>While in the Emergency Department, the patient's mental</br>status was noted to improve gradually.  Although the patient</br>reported having no memory of the days events, he did report</br>being under a fair amount of increased stress over the past</br>several days secondary to his car being stolen and him</br>running out of his standard home medications.  The patient</br>was subsequently admitted to the Medical Intensive Care Unit</br>team for further evaluation and management.</br></br>PAST MEDICAL HISTORY:</br>1. Seizure disorder.</br>2. Parkinson's.</br>3. Coronary artery disease.</br>4. Depression.</br>5. Anxiety.</br></br>HOME MEDICATIONS:</br>1. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Carbidopa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
/
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    levodopa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br>2. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Effexor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br>3. ............</br>4. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Klonopin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br>5. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Metoprolol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br>6. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Diclofenac
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br>7. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lamictal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br>8. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lorazepam
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br></br>ALLERGIES:  No known drug allergies.</br></br>SOCIAL HISTORY:  Lives alone.  Works as a postal worker.</br>Reports a remote history of alcohol abuse, but states the</br>last drink was in [**2170**].  Denies any other history of drug</br>abuse.</br></br>HOSPITAL COURSE:  The patient was admitted to the Medical</br>Intensive Care Unit team under the direction of Dr. [**First Name8 (NamePattern2) **]</br>[**Name (STitle) **] on [**2189-4-2**].  Given the patient's</br>presenting symptoms and his lumbar puncture results, a</br>neurosurgical consult was obtained and the patient was</br>referred for head MRI/MRA which subsequently demonstrated no</br>gross structural abnormalities and no evidence of infarction</br>or intracranial enhancement.</br></br>Over the course of the hospital day #1, the patient's mental</br>status was noted to improve tremendously, and the patient was</br>noted to be fully oriented to person, place, and time.  The</br>patient subsequently stated that he would like to be</br>discharged immediately; however, following discussions with</br>case management and primary team, the patient was convinced</br>to remain in-house for the duration of his medical workup.</br></br>Given the patient's negative head scan and markedly improved</br>mental status with little intervention, the leading diagnosis</br>for his acute mental status change was believed to be a</br>postictal state.  The patient was subsequently restarted on</br>his outpatient seizure and Parkinson's medications to good</br>effect.  In addition, a Psychiatry consultation was obtained</br>who deemed the patient mentally competent, but described him</br>as exhibiting impaired judgement from his recently altered</br>mental status.  The patient was subsequently advised to</br>remain on an one-to-one sitter for risk of elopement, and</br>
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ativan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 standing dosage was recommended given the potential</br>for the patient to go into 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzodiazepine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 withdrawal.</br></br>The patient continued to progress well clinically through</br>hospital day #2, at which point he was cleared for transfer</br>to the regular medical floor, and was admitted to the [**Hospital **]</br>Medical Service.  While on the floor, the patient</br>demonstrated several episodes of acute shortness of breath</br>and tachypnea subsequently ascribed to transient panic</br>attacks that the patient stated were consistent with his</br>normal baseline.</br></br>On [**2189-4-3**], the patient underwent a repeat</br>echocardiogram, which demonstrated severe global left</br>ventricular hypokinesis with an estimated ejection fraction</br>of 25% and 4% mitral regurgitation.  The patient subsequently</br>recommended for a cardiac catheterization, which he underwent</br>on [**2189-4-6**], which subsequently demonstrated three vessel</br>coronary artery disease with 70% proximal irregular stenosis</br>of the left anterior descending artery, total occlusion of</br>the circumflex, and total occlusion of the proximal right</br>coronary artery.  In addition, the patient's cardiac</br>catheterization demonstrated moderate right ventricular</br>diastolic dysfunction, severe left ventricular diastolic</br>dysfunction, moderate primary pulmonary hypertension, and a</br>depressed cardiac index of 1.8.</br></br>Given these findings, a Cardiac Surgery consultation was</br>obtained.  Following a discussion of the relative risks and</br>benefits of surgical intervention, the patient subsequently</br>consented to undergo a coronary artery bypass graft and</br>mitral valve repair to take place on [**2189-4-8**].  On [**2189-4-8**], the patient therefore underwent a coronary artery</br>bypass graft using anastomosis from the LIMA to the LAD, and</br>a mitral annuloplasty using a 28 mm [**Doctor Last Name 405**] ring.  In</br>addition, an intra-aortic balloon pump was inserted via the</br>patient's right femoral artery.  The patient tolerated the</br>procedure well with a bypass time of 122 minutes and a</br>cross-clamp time of 79 minutes.</br></br>Patient's pericardium was left open; lines placed included an</br>arterial line, Swan-Ganz catheter, CVP catheter, and 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IAVP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
;</br>both ventricular and atrial wires were placed; mediastinal</br>and right and left pleural tubes were placed</br>intraoperatively.  The patient was subsequently transferred</br>to the CSRU, intubated, further evaluation and management.</br>On transfer, the patient's mean arterial pressure was 80, his</br>CVP was 19, his ......... was 15 and his [**Doctor First Name 1052**] was 25.  The</br>patient was A-V paced at a rate of 100 beats per minute.</br>Drips on transfer included 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    milrinone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epi
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, and 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    propofol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.</br></br>In the CSRU, the patient's IAVP remained in place through</br>postoperative day #2, at which point it was removed without</br>complication.  The patient demonstrated a gradual respiratory</br>wean, and was finally successfully extubated on postoperative</br>day #3 without complication.  Patient was subsequently</br>advanced to regular oral intake, which he tolerated well</br>through the duration of his stay.</br></br>On postoperative day #4, the patient's PA catheter, pacer</br>wires, and chest tube were removed without complication, and</br>on postoperative day #5, the patient was cleared for transfer</br>to the floor.  The patient was subsequently admitted to the</br>Cardiothoracic Service in the direction of Dr. [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) 1537**].</br></br>On the floor, the patient progressed well clinically through</br>the time of his discharge.  Physical Therapy consultation was</br>obtained, and the patient was cleared for discharge to home</br>following resolution of his acute medical issues.  The</br>patient demonstrated several additional episodes of anxiety</br>attacks through the course of his time on the regular patient</br>floor, all of which responded well to 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ativan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 administration.</br>Patient's Foley catheter was subsequently removed without</br>complication.  He was noted to ............... productive of</br>urine for the duration of his stay.</br></br>On postoperative day #6, a routine chest radiograph</br>demonstrated evidence of a left basilar infiltrate versus</br>atelectasis; the patient was subsequently begun on</br>
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    levofloxacin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 for a 10 day course to be completed as an</br>outpatient.</br></br>On postoperative day #8, [**2189-4-15**], the patient was</br>cleared by Physical Therapy, full independent ambulation.</br>Although Physical Therapy stated that patient would be likely</br>benefit from short rehab stay, the patient clearly stated his</br>preference to return home.  Patient was subsequently cleared</br>for discharge to home with home VNA services and home</br>Physical Therapy on postoperative day #7, [**2189-4-15**].</br></br>CONDITION ON DISCHARGE:  Patient is to be discharged to home</br>with services.</br></br>DISCHARGE STATUS:  Stable.</br></br>DISCHARGE MEDICATIONS:</br>1. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Percocet
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1-2 tablets po q4-6h prn.</br>2. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Colace
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 100 mg po bid.</br>3. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lamotrigine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 115 mg po bid.</br>4. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lopressor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 25 mg po bid.</br>5. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Carbidopa/levodopa
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 25/100 one tablet po tid.</br>6. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Clonidine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 0.1 mg po tid.</br>7. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Captopril
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 6.25 mg po tid.</br>8. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Potassium chloride
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 20 mEq po bid x10 days.</br>9. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Levofloxacin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 500 mg po q day x7 days.</br>10. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 20 mg po bid x10 days.</br>11. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Venlafaxine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 150 mg po q day.</br>12. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Pramipexole dihydrochloride
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1 mg tablet po tid.</br>13. 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lorazepam
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 0.5 mg po q4-6h prn.</br></br>DISCHARGE INSTRUCTIONS:  Patient is to maintain his incisions</br>clean and dry at all times.  The patient may shower, but</br>should pat dry incisions afterwards; no bathing or swimming</br>until further notice.  The patient has been advised to limit</br>his physical activity, no heavy exertion.  The patient has</br>been advised to observe a cardiac diet.  No driving while</br>taking prescription 
<mark class="entity" style="background: #e89ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain medications
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.  The patient is to
receive home VNA services for regular wound checks, and home
physical therapy for strength and endurance training.  The
patient is to followup with the provider of his choice at his
local [**Hospital **] Hospital within 1-2 weeks following discharge.
Patient is to followup with Dr. [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) 1537**] four weeks
following discharge; the patient is to call to schedule his
appointment.




                            [**First Name11 (Name Pattern1) 275**] [**Last Name (NamePattern4) 1539**], M.D.  [**MD Number(1) 1540**]

Dictated By:[**Last Name (NamePattern1) 1053**]
MEDQUIST36

D:  [**2189-4-16**]  01:20
T:  [**2189-4-16**]  05:46
JOB#:  [**Job Number 41061**]
&quot;

</div>
</figure>
</body>
</html>